Guidelines for the management of acute asthma exacerbations recommend noninvasive ventilation as an "experimental approach for treatment of respiratory failure due to severe asthma exacerbation." 1(p398) Clinicians in our tertiary pediat-
ric emergency department have the option to use bilevel positive airway pressure (BiPAP) as treatment for children with asthma exacerbations who have no signs of respiratory failure. We sought to examine whether these patients have improved clinical outcomes.
Methods | The study protocol was approved by the institutional review board of Vanderbilt University. Written informed consent was obtained from the parents and verbal assent from the participants. We performed a secondary analysis of data (which were not deidentified) from a prospective observational study of 933 children and adolescents aged 5 to 17 years who were admitted to our pediatric emergency department with acute asthma exacerbations. The objective of the parent study was to develop a clinical prediction rule for acute asthma exacerbations.
2 For each participant, we performed a comprehensive pulmonary examination and calculated the Acute Asthma Intensity Research Score (AAIRS) before treatment. 3 The clinical team was not provided with the results of the pulmonary examination or the AAIRS. Our primary predictor variable was BiPAP treatment (yes or no) among participants who did not have signs of respiratory failure.
1 Outcomes included hospital admission, admission to the pediatric intensive care unit (PICU), hospital length of stay, and time to spacing of albuterol inhalation to every 4 hours (hereinafter referred to as time to albuterol Q4h) (a metric of exacerbation resolution) based on severity scoring by respiratory therapists. Individual clinicians may, for a given patient, have different preferences for use of BiPAP treatment and different likelihoods for hospital or PICU admission. These preferences may result in confounding by indication, in which BiPAP-treated patients have a risk for relevant outcomes dependent on nonindependent clinician characteristics. Estimating associations of BiPAP treatment with these outcomes in multivariable regression models may not adjust for this confounding. To adjust for confounding by indication, we used propensity scoring that fitted a multiple regression model, with BiPAP treatment as the dependent variable.
4-6 Model predictors included the following covariates that might influence clinician decisions for BiPAP treatment: the individual pretreatment AAIRS components, age, sex, race, Hispanic ethnicity (per the National Institutes of Health Policy on Reporting Race and Ethnicity Data release NOT-OD-01-053, defined by the parent), symptom duration, prior PICU admission for asthma, prior respiratory failure due to asthma, insurance type, and clinician type deciding whether to use BiPAP treatment. The output of this model was a propensity score ranging from 0 to 1 that estimated the adjusted probability of being treated with BiPAP. We then performed propensity score-matching analysis in which BiPAP-treated participants were matched 1:3 by the propensity score with participants not treated with BiPAP, without replacement. We also fitted multiple regression models adjusted for the propensity score and other covariates to examine adjusted associations of BiPAP treatment with each outcome of interest.
Results | Characteristics and univariate associations for the 933 participants are displayed in Table 1 . The median AAIRS in participants treated with BiPAP (n = 45) indicated episodes of moderate severity; the median AAIRS in those not treated with BiPAP (n = 888) indicated episodes of mild to moderate severity. No participant had signs of respiratory failure. The propensity score model yielded a C statistic of 0.895, and the matched groups were very well balanced on the covariates. Results of propensity score matching and propensity scoreadjusted multivariable regression models are presented in Table 2 . Those participants treated with BiPAP were more likely to be admitted to the hospital or to the PICU and did not differ in length of stay or time to albuterol Q4h. Discussion | Our results indicate that BiPAP treatment of children and adolescents with acute asthma exacerbations who have no signs of impending respiratory failure is associated with a greater likelihood of hospital and PICU admission and no apparent benefit in decreased length of stay or time to albuterol Q4h. Propensity score analyses have been proposed as a method to estimate the causal effect of an exposure. 4, 6 Nonetheless, this study is limited because it cannot resolve whether these findings are a consequence of clinical momentum after positive pressure ventilation or of increased air trapping and ventilation-perfusion mismatch, derangements that worsen an exacerbation. A randomized clinical trial should be performed before BiPAP is used in children with acute asthma exacerbations without respiratory failure. f Indicates time to spacing of albuterol inhalation to Q4h (a metric of exacerbation resolution). g Analyzed using ordinal logistic regression models owing to skewness of these outcome variables; adjusted ORs are for a 1-hour increase in time for outcome of interest.
Accuracy of Bayley Scores as Outcome Measures in Trials of Neonatal Therapies
Long-term follow-up of extremely preterm infants is essential because the proportion of infants who survive is increasing while neurodevelopmental impairment rates remain high.
1
Psychometric tests, such as the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III), 2 are commonly used to measure early childhood outcomes in obstetric and neonatal randomized trials. 3, 4 However, the composite scores on psychometric tests can be inaccurate because of administrative and technical errors. To determine the magnitude of this problem, we performed a post hoc review of all errors detected by central source document verification of Bayley-III assessments during the 18-month follow-up of the Canadian Oxygen Trial (COT).
5
Methods | Extremely preterm COT participants in 25 centers in 6 countries were randomly assigned to 2 oxygen saturation target ranges. The primary outcome at a corrected age of 18 to 21 months was death or survival with neurodevelopmental disability. Cognitive or language composite scores of less than 85 on the Bayley-III scales were included in the primary outcome.
The research ethics boards of all clinical centers approved the protocol, and written informed consent was obtained from a parent or guardian of every study infant.
Original Review Process During COT. Experienced examiners administered the Bayley-III test and submitted copies of the source documents to the coordinating center. Between October 15, 2008, and August 15, 2012, trained staff (J.D. and L.C.) reviewed the source documents for accuracy, completeness, and agreement with the electronic database entries. Discrepancies were identified and corrected through a formal data clarification process with input from Bayley-III examiners at the respective study sites. A small number of queries (n = 36) could not be resolved directly with the clinical centers and were referred to an adjudication committee consisting of a developmental pediatrician (D.M.) and a neurodevelopmental consultant (K.P.).
Post Hoc Analysis. In this study, 1 assessor (J.D.) reexamined all Bayley-III source documents and classified the errors that were identified during the original review process into 5 categories: calculation of the child's corrected age, documenting or applying scoring rules, raw score addition, look-up of scaled scores and composite scores in normative tables, and electronic data entry. A 15% random sample was independently classified by a second assessor (L.C.) to ensure consistent classification of error types. Only 2 disagreements were found and resolved through consensus. The error categories are hierarchical in nature. An early mistake-for example, calculation of the corrected age-may affect all subsequent steps. We counted such errors only once, assigned them to the category in which they first occurred, and summarized the frequency of independent errors in each of the 5 categories.
Results | During COT follow-up, the source documents for 936 of 954 (98.1%) Bayley-III assessments were submitted to the coordinating center. Eighteen children could not be evaluated because of severe developmental delay or autism. Of 936 source documents, 576 (61.5%) contained no errors. The remaining 360 (38.5%) contained at least 1 error, and the total number of independent errors was 387 (Table) . None of the 25 clinical centers were completely error free. The best and worst center-specific error rates were 8 of 61 (13.1%) and 14 of 16 (87.5%), respectively. Had they not been detected during the original review process, 41 of 387 (10.6%) incorrectly reported composite scores would have changed the determination of the composite primary outcome in COT.
Discussion | Experienced Bayley-III examiners made numerous administrative, scoring, and reporting errors in this inter- 
